Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
national blog main
national top stories
new york blog main
new york top stories
9
×
san diego blog main
san diego top stories
9
×
san francisco blog main
san francisco top stories
vc
9
×
biotech
life sciences
detroit blog main
detroit top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
venture capital
gene therapy
ipo
biogen
celgene
fda
gene editing
novartis
startups
cancer
deals
scott gottlieb
What
bio
roundup
ipo
new
biogen
gene
healthcare
investors
medicine
medicines
moves
remains
therapy
abbvie’s
activity
aiming
allogene
ambys
america
approvals
attributes
barbecuing
becker
big
billions
biopharma
biotech
camping
cancer
car
cardiologist
celgene
center
charm
check
cholesterol
clamped
colleagues
conference
continues
Language
unset
Current search:
vc
×
" new york top stories "
×
" san diego top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
4 years ago
Review: Inside the House of Lies at Theranos
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?